Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases

References

• Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165-80
   PubMed Web of Science ®Google Scholar
• National kidney and urologic diseases information clearinghouse (NKUDIC). Available from: www.kidney.niddk.nih.gov/kudiseases/pubs/kustats/
   Google Scholar
• Tesauro M, Mascali A, Franzese O, et al. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin. Int J Hypertens 2012;2012:943605
   Google Scholar
• O’seaghdha CM, Lyass A, Massaro JM, et al. A risk score for chronic kidney disease in the general population. Am J Med 2012;125(3):270-7
   Google Scholar
• Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South Med J 2010;103(2):140-6
   Google Scholar
• Cai G, Zheng Y, Sun X, Chen X. Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China. J Am Geriatr Soc 2013;61(12):2160-7
   PubMed Web of Science ®Google Scholar
• Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988;296(6616):156-60
   Web of Science ®Google Scholar
• Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010;77(1):57-64
   PubMed Web of Science ®Google Scholar
• Mischak H, Coon JJ, Novak J, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009;28(5):703-24
   PubMed Web of Science ®Google Scholar
• Pejcic M, Stojnev S, Stefanovic V. Urinary proteomics--a tool for biomarker discovery. Ren Fail 2010;32(2):259-68
   PubMed Web of Science ®Google Scholar
• Heinzmann SS, Merrifield CA, Rezzi S, et al. Stability and robustness of human metabolic phenotypes in response to sequential food challenges. J Proteome Res 2012;11(2):643-55
   PubMed Web of Science ®Google Scholar
• Winnike JH, Busby MG, Watkins PB, O’connell TM. Effects of a prolonged standardized diet on normalizing the human metabolome. Am J Clin Nutr 2009;90(6):1496-501
   Google Scholar
• Mischak H, Kaiser T, Walden M, et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci 2004;107(5):485-95
   Google Scholar
• Weissinger EM, Wittke S, Kaiser T, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004;65(6):2426-34
   PubMed Web of Science ®Google Scholar
• Chalmers MJ, Mackay CL, Hendrickson CL, et al. Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem 2005;77(22):7163-71
   PubMed Web of Science ®Google Scholar
• Haubitz M, Wittke S, Weissinger EM, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005;67(6):2313-20
   PubMed Web of Science ®Google Scholar
• Sharma K, Lee S, Han S, et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005;5(10):2648-55
   Google Scholar
• Rao PV, Lu X, Standley M, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30(3):629-37
   PubMed Web of Science ®Google Scholar
• Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics. Clin Appl 2007;1(2):148-56
   PubMed Web of Science ®Google Scholar
• Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010;2(46):46ps42
   PubMed Web of Science ®Google Scholar
• Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 2012;42(9):1027-36
   PubMed Web of Science ®Google Scholar
• Mischak H, Vlahou A, Righetti PG, Calvete JJ. Putting value in biomarker research and reporting. J Proteomics 2014;96:A1-3
   PubMed Web of Science ®Google Scholar
• Schanstra JP, Mischak H. Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Siwy J, Schanstra JP, Argiles A, et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant 2014. [Epub ahead of print]
   Google Scholar
• Decramer S, Gonzalez De PA, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics 2008;7(10):1850-62
   PubMed Web of Science ®Google Scholar
• Thongboonkerd V. Recent progress in urinary proteomics. Proteomics Clin Appl 2007;1(8):780-91
   Web of Science ®Google Scholar
• Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7(3):230-40
   PubMed Web of Science ®Google Scholar
• Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010;17(6):493-506
   PubMed Web of Science ®Google Scholar
• Fliser D, Wittke S, Mischak H. Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes. Electrophoresis 2005;26(14):2708-16
   Google Scholar
• Standard protocol for urine collection. Available from: www.eurokup.org/sites/default/files/StandardProtocolforUrineCollection.pdf
   Google Scholar
• Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J kidney Dis 2013;62(3):595-603
   PubMed Web of Science ®Google Scholar
• Liu KD, Yang W, Anderson AH, et al. Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int 2013;83(5):909-14
   PubMed Web of Science ®Google Scholar
• Chou KM, Lee CC, Chen CH, Sun CY. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS One 2013;8(1):e54863
   PubMed Web of Science ®Google Scholar
• Rau S, Habicht A, Kauke T, et al. Neutrophil gelatinase-associated lipocalin and end-stage renal disease: it is not all about the kidneys!. Eur J Clin Invest 2013;43(8):816-20
   PubMedGoogle Scholar
• Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci 2005;108(5):369-83
   PubMed Web of Science ®Google Scholar
• Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007;18(4):1057-71
   PubMed Web of Science ®Google Scholar
• Decramer S, Gonzalez De Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics 2008;7(10):1850-62
   PubMed Web of Science ®Google Scholar
• Dakna M, Harris K, Kalousis A, et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010;11:594
   PubMed Web of Science ®Google Scholar
• Dakna M, He Z, Yu WC, et al. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(13):1250-8
   Web of Science ®Google Scholar
• Mischak H, Massy ZA, Jankowski J. Proteomics in uremia and renal disease. Semin Dial 2009;22(4):409-16
   PubMed Web of Science ®Google Scholar
• Mullen W, Delles C, Mischak H, Euro KUPCA. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20(6):654-61
   PubMed Web of Science ®Google Scholar
• Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9(11):2424-37
   PubMed Web of Science ®Google Scholar
• Cheng S, Pollock AS, Mahimkar R, et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006;20(11):1898-900
   PubMed Web of Science ®Google Scholar
• Argiles A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013;8(5):e62837
   PubMed Web of Science ®Google Scholar
• Siwy J, Mullen W, Golovko I, et al. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 2011;5(5-6):367-74
   PubMed Web of Science ®Google Scholar
• Zurbig P, Decramer S, Dakna M, et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009;9(8):2108-17
   PubMed Web of Science ®Google Scholar
• Merchant ML, Perkins BA, Boratyn GM, et al. Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and Microalbuminuria. J Am Soc Nephrol 2009;20(9):2065-74
   PubMed Web of Science ®Google Scholar
• Alkhalaf A, Zurbig P, Bakker SJ, et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010;5(10):e13421
   PubMed Web of Science ®Google Scholar
• Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19(7):1283-90
   PubMed Web of Science ®Google Scholar
• Molin L, Seraglia R, Lapolla A, et al. A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. J Proteomics 2012;75(18):5888-97
   PubMed Web of Science ®Google Scholar
• Lapolla A, Molin L, Sechi A, et al. A further investigation on a MALDI-based method for evaluation of markers of renal damage. J Mass Spectrom 2009;44(12):1754-60
   PubMed Web of Science ®Google Scholar
• Andersen S, Mischak H, Zurbig P, et al. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010;11:29
   Google Scholar
• Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012;61(12):3304-13
   PubMed Web of Science ®Google Scholar
• Roscioni SS, De Zeeuw D, Hellemons ME, et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013;56(2):259-67
   PubMed Web of Science ®Google Scholar
• Caseiro A, Barros A, Ferreira R, et al. Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. Transl Res 2014;163(3):188-99
   PubMed Web of Science ®Google Scholar
• Haubitz M, Good DM, Woywodt A, et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009;8(10):2296-307
   PubMed Web of Science ®Google Scholar
• Carty DM, Siwy J, Brennand JE, et al. Urinary proteomics for prediction of preeclampsia. Hypertension 2011;57(3):561-9
   PubMed Web of Science ®Google Scholar
• Kalantari S, Rutishauser D, Samavat S, et al. Urinary prognostic biomarkers and classification of iga nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PloS One 2013;8:12
   Google Scholar
• Takahashi K, Wall SB, Suzuki H, et al. Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics 2010;9(11):2545-57
   PubMedGoogle Scholar
• Drube J, Zurbig P, Schiffer E, et al. Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol 2010;25(9):1673-8
   PubMed Web of Science ®Google Scholar
• Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006;12(4):398-400
   PubMed Web of Science ®Google Scholar
• Stalmach A, Albalat A, Mullen W, Mischak H. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 2013;34(11):1452-64
   PubMed Web of Science ®Google Scholar
• Fuchs JE, Von Grafenstein S, Huber RG, et al. Cleavage entropy as quantitative measure of protease specificity. PLOS Comput Biol 2013;9(4):e1003007
   PubMed Web of Science ®Google Scholar
• Klingler D, Hardt M. Profiling protease activities by dynamic proteomics workflows. Proteomics 2012;12(4-5):587-96
   PubMed Web of Science ®Google Scholar
• Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. Theranostics 2012;2(2):156-78
   PubMed Web of Science ®Google Scholar
• Castro HC, Abreu PA, Geraldo RB, et al. Looking at the proteases from a simple perspective. J Mol Recognit 2011;24(2):165-81
   PubMed Web of Science ®Google Scholar
• Quertle. Available from: www.quertle.info
   Google Scholar
• Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35(1):1-10
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010;1803(1):39-54
   PubMed Web of Science ®Google Scholar
• Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 2012;302(11):F1351-61
   PubMed Web of Science ®Google Scholar
• Van Der Zijl NJ, Hanemaaijer R, Tushuizen ME, et al. Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: a marker of incipient diabetic nephropathy? Clin Biochem 2010;43(7-8):635-9
   Web of Science ®Google Scholar
• Altemtam N, Nahas ME, Johnson T. Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression. Nephron Extra 2012;2:219-32
   Google Scholar
• Caseiro A, Ferreira R, Quintaneiro C, et al. Protease profiling of different biofluids in type 1 diabetes mellitus. Clin Biochem 2012;45(18):1613-19
   Google Scholar
• Jiang Z, Sui T, Wang B. Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis. Rheumatol Int 2010;30(9):1219-26
   PubMed Web of Science ®Google Scholar
• Zakiyanov O, Kalousova M, Kratochvilova M, et al. Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease. Clin Lab 2012;58(5-6):471-80
   Google Scholar
• Zakiyanov O, Kalousova M, Kratochvilova M, et al. Changes in levels of matrix metalloproteinase-2 and -9, pregnancy-associated plasma protein-A in patients with various nephropathies. J Nephrol 2013;26(3):502-9
   Google Scholar
• Ban CR, Twigg SM, Franjic B, et al. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res Clin Pract 2010;87(3):335-41
   Google Scholar
• Peiskerova M, Kalousova M, Kratochvilova M, et al. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res 2009;32(4):276-83
   Google Scholar
• Hsu TW, Kuo KL, Hung SC, et al. Progression of kidney disease in non-diabetic patients with coronary artery disease: predictive role of circulating matrix metalloproteinase-2, -3, and -9. PLoS One 2013;8(7):e70132
   Google Scholar
• Smith ER, Tomlinson LA, Ford ML, et al. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension 2012;59(5):973-8
   PubMed Web of Science ®Google Scholar
• Musial K, Zwolinska D. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones 2011;16(1):97-103
   PubMed Web of Science ®Google Scholar
• Musial K, Zwolinska D. Novel indicators of fibrosis-related complications in children with chronic kidney disease. Clin Chim Acta 2013;430C:15-19
   Google Scholar
• Pawlak K, Mysliwiec M, Pawlak D. Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clin Biochem 2011;44(10-11):838-43
   Google Scholar
• Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013;226(2):305-14
   PubMed Web of Science ®Google Scholar
• Sun AL, Deng JT, Guan GJ, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res 2012;9(4):301-8
   PubMed Web of Science ®Google Scholar
• Tinoco AD, Tagore DM, Saghatelian A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc 2010;132(11):3819-30
   Google Scholar
• Pollheimer J, Fock V, Knofler M. Review: The ADAM metalloproteinases - Novel regulators of trophoblast invasion? Placenta 2014;35S:S57-63
   Google Scholar
• Van Der Vorst EP, Keijbeck AA, De Winther MP, Donners MM. A disintegrin and metalloproteases: molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012;224(2):302-8
   Google Scholar
• Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development 2012;139(20):3693-709
   Web of Science ®Google Scholar
• Shen L, Lu G, Dong N, et al. Von Willebrand factor, ADAMTS13 activity, TNF-alpha and their relationships in patients with chronic kidney disease. Exp Ther Med 2012;3(3):530-4
   Google Scholar
• Gutwein P, Schramme A, Abdel-Bakky MS, et al. ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases. J Biomed Sci 2010;17:3
   Google Scholar
• Wickstrom M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 2011;102(3):501-8
   PubMed Web of Science ®Google Scholar
• Moon PG, Lee JE, You S, et al. Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 2011;11(12):2459-75
   PubMed Web of Science ®Google Scholar
• Klein J, Eales J, Zurbig P, et al. Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics 2013;13(7):1077-82
   PubMed Web of Science ®Google Scholar
• Siwy J, Zoja C, Klein J, et al. Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One 2012;7(12):e51334
   PubMed Web of Science ®Google Scholar
• Dominiczak AF, Herget-Rosenthal S, Delles C, et al. Systems biology to battle vascular disease. Nephrol Dial Transplant 2010;25(4):1019-22
   PubMed Web of Science ®Google Scholar